Our results concluded that coumarin derivative DBH2 serves as a promising candidate for the CML treatment, especially in the combination with imatinib for the TKI resistant CML, and STAT/caspase-3 pathway was involved in the molecular mechanism of anti-leukemic activity of DBH2. This evidence concerns the gene SOAT1 and chronic myelogenous leukemia, BCR-ABL1 positive.